Access to Information Requests Completed - June 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you contact the Access to Information and Privacy Division.

Completed Requests

For the month of June 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2009-00752	Documents pertaining to the Information Update issued by Health Canada on September 17, 2009 relating to Apotex products.	Disclosed in part	345
A-2009-00757	Any information pertaining to plain or generic packaging for tobacco products. (Sep 24, 2004 to Sep 23, 2009).	Disclosed in part	744
A-2009-01445	Documents regarding the supply by AECL of isotopes to the medical community, whether via MDS Nordion or otherwise. (Jun 4, 2008 to Mar 25, 2010).	Disclosed in part	426
A-2010-00112	All documents pertaining to any trade or consumer complaint filed against the following company: Les Laboratories Nicar Inc.	Disclosed in part	356
A-2010-00458	Information regarding the product Eloxatin, DIN 02296284 by Sanofi-Aventis.	Disclosed in part	207
A-2010-00977	Information regarding the following medical devices: Depuy ASR XL Acetabular Cup System, Depuy ASR Articular Surface Replacement System and ASR Acetabular Cup System. (Jan 1, 2006 to Dec 14, 2010).	Disclosed in part	762
A-2010-01317	All correspondence and/or Air Bills between Aeromedical Emergency Services 1988 Ltd and/or 1043374 AB Ltd and Health Canada. (Jan 1, 2010 to Dec 10, 2010).	Disclosed in part	437
A-2010-01445	All documents regarding to the Supreme Court's ruling on December 22, 2010 related to the Assisted Human Reproduction Act and the Assisted Human Reproduction Canada.	Disclosed in part	1,236
A-2010-01482	Information regarding the product Diflucan One by Pfizer.	Disclosed in part	27
A-2011-00247	All documents relating to information provided to Health Canada in 2009 regarding Electronic Health Information and Communication Technology (EHICT) projects funded by Canada Health Infoway Inc.	Disclosed in part	19
A-2011-00249	All document relating to information provided to Health Canada in 2011 regarding Electronic Health Information and Communication Technology (EHICT) projects funded by Canada Health Infoway Inc.	Disclosed in part	26
A-2011-00483	All documents in relation to Metribuzin as detailed in the Proposed Acceptability for Continuing Registration (PACR2005-07) and the Re-evaluation Decision Document (RRD2006-15).	Disclosed in part	407
A-2011-00507	Information regarding the product Enteric Coated Daily Low Dose ASA 81mg, DIN 02363127 by Vita Health Products Inc.	Disclosed in part	512
A-2011-00686	Information regarding the product PMS-PROPOFOL, DIN 02244379 by PharmaScience.	Disclosed in part	686
A-2011-00951	All documents relating to meetings on the Loblaw's Guiding Stars program.	Disclosed in part	103
A-2011-00988	All documents relating to the assessment of the safety and efficacy of the following enzyme: Amylase.	All disclosed	37
A-2011-00989	All documents relating to the assessment of the safety and efficacy of the following enzyme: Lipase.	All disclosed	39
A-2011-00990	All documents relating to the assessment of the safety and efficacy of the following enzyme: Cellulase.	All disclosed	39
A-2011-00991	All documents relating to the assessment of the safety and efficacy of the following enzyme: Trypsin.	All disclosed	39
A-2011-00992	All documents relating to the assessment of the safety and efficacy of the following enzyme: Chymotrypsin.	All disclosed	100
A-2011-01373	All records related to the Federal/Provincial/Territorial Task Group on Sodium. (Dec 1, 2011 to Dec 15, 2011).	Disclosed in part	37
A-2011-01379	All documents regarding claims made by companies producing fortified beverages (also known as functional beverages) including but not limited to Vitaminwater, Aquafina Plus and Propel.	Disclosed in part	488
A-2011-01425	Information regarding the product Herpestat Lip Shield, NPN 80009769 by Origin BioMed Inc.	Disclosed in part	269
A-2011-01447	AERs for the product Norvir. Report numbers: 000369359 and 000368480.	Disclosed in part	20
A-2011-01482	Information regarding NPN 80012573.	Disclosed in part	45
A-2011-01483	Information regarding NPN 80012574.	Disclosed in part	44
A-2011-01501	Documents relating to the Health needs assessment for the last three Health Canada funded First Nation stand-alone health centers on reserve.	Disclosed in part	254
A-2011-01543	All documents regarding the management, regulation and work on the certification requirements of ski and snowboard helmets. (Jan 1, 2011 to Feb 8, 2012).	Disclosed in part	535
A-2011-01583	Information regarding the product JAMP-A.S.A., DIN 02283905 by Jamp Pharma Corporation.	Disclosed in part	51
A-2011-01598	AERs for the product Epival. Report numbers: 000372374 and 000369822.	Disclosed in part	4
A-2011-01615	AER for the product Gliclazide MR 60 mg. Report number: 000375169.	Disclosed in part	1
A-2011-01635	All documents generated as a result of Canadian Broadcasting Corporation (CBC) inquiries/question/interview request/research request and stories that have aired, in relation to asbestos and/or chrysotile. (May 1, 2011 to Mar 9, 2012)	Disclosed in part	934
A-2011-01714	AER for the product Gadovist. Report number: 000382553.	Disclosed in part	7
A-2011-01732	Information regarding the product Eucalyptus Oil, NPN 00399620 by RW Packing Ltd.	Disclosed in part	46
A-2011-01742	AERs for the product Humira. Report numbers: 000366262, 000367063, 000368295, 000370435, 000370932 and 000371648.	Disclosed in part	37
A-2011-01761	All comments received in response to the February 17 2012 consultation for the proposed Group 2 Regulations under the Lead Risk Reduction Strategy for Consumer Products.	All disclosed	68
A-2012-00024	The 2007 Assisted Human Reproduction Canada  (AHRC) draft or final document titled Assisted Human Reproduction Act Section 8 (Consent) Regulations Guidance Document.	All disclosed	24
A-2012-00028	All documents related to a meeting between NorTerra Inc. and Leona Aglukkaq held on July 11, 2009.	Disclosed in part	2
A-2012-00040	Internal audit of management processes for the Marihuana Medical Access program completed in 2007, and any subsequent audits or departmental analysis. (Jan 1, 2007 to Apr 12, 2012).	Disclosed in part	223
A-2012-00043	AERs for the product Pantoloc. Report numbers: 000380605, 000382147 and 000392180.	Disclosed in part	7
A-2012-00057	AER for the product Omnaris. Report number: 000381171.	Disclosed in part	1
A-2012-00061	A copy of the three reports submitted to Health Canada by Canada Health Infoway (CHI) on October 30, 2010 and semi-annually thereafter beginning June 30, 2011 detailing CHI's progress against the objectives of its current Funding Agreement.	All disclosed	12
A-2012-00073	AER for the product Humulin. Report number: 000389327.	Disclosed in part	8
A-2012-00076	A copy of the Record of Proceedings (June 5-6, 2008) of the Expert Advisory Panel for Health Canada's Special Access Programme.	All disclosed	15
A-2012-00085	AER for the product MIRAPEX. Report number: 000367037.	Disclosed in part	1
A-2012-00086	AERs for the product PRADAX. Report numbers: 000361146, 000370589, 000368675, 000371536, 000379609 and 000376653.	Disclosed in part	14
A-2012-00087	AERs for the product MICARDIS PLUS. Report numbers: 000367162 and 000347825.	Disclosed in part	2
A-2012-00103	AERs. Report numbers: 000381026 and 000384671.	Disclosed in part	3
A-2012-00111	Lists of contracts awarded to advertising firms or agencies. (Jan 1, 2005 to Apr 23, 2012).	All disclosed	19
A-2012-00112	All document indicating the total dollar amounts paid out annually by your department to legal firms or to staff or outside counsel. (Jan 1, 2005 to Apr 23, 2012).	All disclosed	7
A-2012-00118	Adverse Event Case for Sertraline that was published in the Canadian Adverse Reaction Newsletter, Volume 22, Issue 2, April 2012, Referring to case 2 (38 year-old female) for Sertraline found in Table 1 on page 3 of 4 of the above mentioned newsletter.	Disclosed in part	8
A-2012-00141	Question Period briefing notes provided to Health Minister Leona Aglukkaq on April 23, 2012.	All disclosed	44
A-2012-00144	All contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of April 2012.	All disclosed	8
A-2012-00146	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of April 2012.	Disclosed in part	113
A-2012-00147	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during April 2012.	All disclosed	1
A-2012-00153	All call-ups/Contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Translation Services during the period of March-April 2012.	Disclosed in part	107
A-2012-00155	AER. Report number: 000370674.	Disclosed in part	2
A-2012-00156	AER. Report number: 000371214.	Disclosed in part	1
A-2012-00157	AER. Report number: 000367282.	Disclosed in part	1
A-2012-00158	AER. Report number: 000369341.	Disclosed in part	1
A-2012-00162	AER. Report number: 000379503.	Disclosed in part	4
A-2012-00169	A listing of the Access to Information requests submitted to Health Canada. (Apr 1, 2012 to Apr 30, 2012).	Disclosed in part	10
A-2012-00173	Product Monograph for the product Novo-Ciprofloxacin, DINs 02161737, 02161745 and 02161753.	All disclosed	37
A-2012-00174	Product Monograph for the product Novo-Norfloxacin, DIN 02237682.	All disclosed	111
A-2012-00175	Product Monograph for the product Novo-Levofloxacin, DIN 02248262, 02248263 and 02285649.	All disclosed	218
A-2012-00176	Product Monograph for the products: Ciprofloxacin (250, 500 & 700mg tablets), Ran-Ciproflox, Ran-Ciprofloxacin, Apo-Ciproflox, Cipro, CO-Ciprofloxacin, DOM- Ciprofloxacin, Riva-Ciprofloxacin, Mylan-Ciprofloxacin, Gen-Ciprofloxacin, PHL- Ciprofloxacin, PMS-Ciprofloxacin, Sandoz-Ciprofloxacin, Rhoxal-Ciprofloxacin and Taro- Ciprofloxacin.	All disclosed	838
A-2012-00178	Product Monograph for the products: Levofloxacin (250, 500 & 750 mg tablets), Levaquin and Apo-Levofloxacin.	All disclosed	1,148
A-2012-00179	List of all supply contracts for health care or drugs and the value of each contract in the following areas: First Nations, Inuit and Aboriginal Health (NIHB Program); Royal Canadian Mounted Police; Armed Forces; Armed Forces Veterans; and Correctional Service of Canada. (Jan 1, 2006 to Apr 28, 2012).	All disclosed	116
A-2012-00181	All contracts processed by this institution in the National Capital Region for the procurement of Temporary Help Services during the period of March 2012.	Disclosed in part	3
A-2012-00184	All submissions, including written and by way of presentation, made to Health Canada about amendments to the reference to nicotine and its salts for human use, in Part I of Schedule F to the Food and Drug Regulations.	No records exist	0
A-2012-00191	All documents regarding the government's decision to close Assisted Human Reproduction Canada effective March 1, 2013. (Jan 1, 2012 to Feb 1, 2012)	No records exist	0
A-2012-00197	A list of all audits conducted by the department on anti-tobacco/anti-smoking programs. (Jan 1, 2011 to May 11, 2012).	All disclosed	1
A-2012-00198	All documents related to potential safety risk with respect to the Apogee System with IntePro™. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	82
A-2012-00199	User Manual or patient leaflet for Apogee System with Intepro™. (Jan 1, 1996 to May 7, 2012).	All disclosed	4
A-2012-00201	All documents related to potential safety risk with respect to the Perigee System with IntePro™. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	82
A-2012-00202	User Manual or patient leaflet for Perigee System with Intepro™. (Jan 1, 1996 to May 7, 2012).	All disclosed	4
A-2012-00204	All documents related to potential safety risk with respect to the MiniArc Sling System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	82
A-2012-00209	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product Bioarc SP Sling Kit. (Jan 1, 1996 to May 7, 2012).	No records exist	0
A-2012-00210	All documents related to potential safety risk with respect to the Bioarc SP Sling Kit. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	82
A-2012-00211	User Manual or patient leaflet for Bioarc SP Sling Kit. (Jan 1, 1996 to May 7, 2012).	No records exist	0
A-2012-00213	All documents related to potential safety risk with respect to the Sparc Sling System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	82
A-2012-00214	User Manual or patient leaflet for Sparc Sling System. (Jan 1, 1996 to May 7, 2012).	All disclosed	53
A-2012-00217	All radon measurements collected during Phase 2 of the Cross Canada Residential Radon Survey.	All disclosed	150
A-2012-00256	All documents related to potential safety risk with respect to the INTERCEED Absorbable Adhesion Barrier. (Jan 1, 1996 to May 7, 2012).	No records exist	0
A-2012-00257	User Manual or patient leaflet for INTERCEED Absorbable Adhesion Barrier. (Jan 1, 1996 to May 7, 2012).	All disclosed	9
A-2012-00258	All documents related to potential safety risk with respect to the Morcellex Tissue Morcellator. (Jan 1, 1996 to May 7, 2012).	All disclosed	4
A-2012-00260	User Manual or patient leaflet for Morcellex Tissue Morcellator. (Jan 1, 1996 to May 7, 2012).	No records exist	0
A-2012-00262	All documents related to potential safety risk with respect to the GYNECARE PROLIFT +M Pelvic Floor Repair System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	82
A-2012-00280	All documents considered in the decision to exclude menthol as a prohibited additive in Bill C-32. (Jan 1, 2008 to May 18, 2012).	All disclosed	58
A-2012-00281	Bovine Spongiform Encephalopathy (BSE). Summative Evaluation of the BSE I (Augmenting Health Canada's Response to the BSE) and BSE II (Further Measures on BSE in the Areas of Risk Assessment and Targeted Research) Initiatives.	All exempted	0
A-2012-00282	List of drugs supplied through the Special Access Program by volume and manufacturer. (May 23, 2011 to May 22, 2012).	All disclosed	14
A-2012-00297	All documents related to the TVT-O transvaginal mesh sling bearing lot number 3070426.	All disclosed	4
A-2012-00298	All documents related to the Prolene Soft transvaginal mesh sling bearing lot number NOXBE136.	Disclosed in part	84
A-2012-00299	All documents related to the PRO LIFT transvaginal mesh sling system, bearing lot number 3283377.	All disclosed	4
A-2012-00300	All documents related to the American Medical Systems SPARC TM transvaginal mesh sling system, bearing lot number 5825906X.	Disclosed in part	82
A-2012-00301	All documents related to the Tyco Healthcare transvaginal mesh sling, Reference IVS-02, bearing lot number 04F-109.	Disclosed in part	82
A-2012-00309	AER. Report number: 000403205.	Disclosed in part	3
A-2012-00331	All documents regarding any proposed taxation of sugar-sweetened beverages raised in relation to the Chronic diseases related to aging and health promotion and diseases prevention: Report of the Standing Committee on Health (May 2012) report issued by the standing Committee on Health on or around May 15, 2012. (Jan 1, 2012 to Jun 1, 2012).	No records exist	0
A-2012-00337	Antidandruff: Category IV Monograph.	All disclosed	4
A-2012-00338	Antiperspirants: Product monograph from July 28, 2006.	All disclosed	10
A-2012-00340	Antiseptic Skin Cleansers: Category IV Monograph.	All disclosed	3
A-2012-00341	Athlete's Foot treatments: Therapeutic Product Directorate Category IV Monograph.	All disclosed	5
A-2012-00342	Caffeine: Labelling Standard.	All disclosed	2
A-2012-00343	Chamomile: Labelling Standard.	All disclosed	5
A-2012-00384	All incident reports on injury associating with the use of cosmetic contact lenses within Canada. (Jan 1, 2000 to Jun 7, 2012).	Disclosed in part	37
A-2012-00399	All documents regarding the transformation of NeuroScience Canada Foundation into the Brain Canada Foundation. (Jan 1, 2009 to May 8, 2012).	No records exist	0
A-2012-00401	Information regarding the product Teva-Lamivudine/Zidovudine, DIN 02387247 by Teva Canada Limited.	All exempted	0
A-2012-00407	Any documents relating to performance enhancing substances and hockey (amateur or professional). Jan 1, 2004 to Jul 31, 2006).	No records exist	0
A-2012-00432	All reports to Health Minister from committee formed as per recommendation #55 of Weatherill report Considering the serious implications of foodborne illnesses, governments should create a distinct federal, provincial and territorial committee reporting regularly to the federal Minister of Health. (Sep 1, 2009 to Jun 7, 2012).	No records exist	0